Piramal Pharma Ltd (PPLPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003728,
    "name": "Piramal Pharma",
    "stock_name": "Piramal Pharma",
    "full_name": "Piramal Pharma Ltd",
    "name_url": "stocks-analysis/piramal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "160.45",
    "chg": -2.95,
    "chgp": "-1.81%",
    "dir": -1,
    "prev_price": "163.40",
    "mcapval": "21,947.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543635,
    "symbol": "PPLPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE0DK501011",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "38.76 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/piramal-pharma-1003728-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Piramal Pharma Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/piramal-pharma-ltd-is-rated-sell-by-marketsmojo-3989390",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PiramalPharmaLt_mojoScore_3989390.png",
        "date": "2026-05-13 10:10:03",
        "description": "Piramal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Piramal Pharma Gains 12.13%: 5 Key Factors Driving the Week’s Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-gains-1213-5-key-factors-driving-the-weeks-rally-3982997",
        "imagepath": "",
        "date": "2026-05-09 11:02:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Flat quarterly financial trend reported amid mixed performance</p>\n                    <p><strong>5 May:</strong> Technical momentum shifts with mildly bearish signals</p>\n                    <p><strong>7 May:</strong> Intraday high surge of 8.42% and exceptional volume spike</p>\n                    <p><strong>7 May:</strong> Surge in value trading and institutional interest</p>\n                    <p><strong>7 May:</strong> Exceptional volume surge amid strong price rally</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.160.30</div></div>..."
      },
      {
        "title": "Piramal Pharma Ltd Sees Exceptional Volume Surge Amid Strong Price Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-sees-exceptional-volume-surge-amid-strong-price-rally-3979822",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PiramalPharmaLt_most_active_equities_by_volume_3979822.png",
        "date": "2026-05-07 12:00:06",
        "description": "Piramal Pharma Ltd (PPLPHARMA) has emerged as one of the most actively traded stocks on 7 May 2026, registering a remarkable surge in volume and price amidst heightened volatility. The pharmaceutical and biotechnology small-cap stock outperformed its sector and broader market indices, signalling strong investor interest despite a recent downgrade in its mojo grade from Hold to Sell."
      },
      {
        "title": "Piramal Pharma Ltd Sees Surge in Value Trading Amid Volatility and Institutional Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-sees-surge-in-value-trading-amid-volatility-and-institutional-interest-3979824",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PiramalPharmaLt_most_active_equities_by_value_3979824.png",
        "date": "2026-05-07 12:00:05",
        "description": "Piramal Pharma Ltd (PPLPHARMA) emerged as one of the most actively traded stocks by value on 7 May 2026, registering a remarkable 12.39% intraday gain and outperforming its sector by over 14%. The pharmaceutical small-cap has attracted significant institutional interest, with trading volumes soaring to nearly 3 crore shares and a total traded value exceeding ₹551 crore, signalling heightened investor participation amid volatile market conditions."
      },
      {
        "title": "Piramal Pharma Ltd Surges 8.42% to Day's High of Rs 175.7 — Outperforms Sector by 6.05 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-hits-intraday-high-with-842-surge-on-7-may-2026-3979764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PiramalPharmaLt_priceRelatedfactors_3979764.png",
        "date": "2026-05-07 11:16:01",
        "description": "The Sensex declined 0.18% on 7 May 2026, while Piramal Pharma Ltd surged 8.42%, outperforming its Pharmaceuticals &amp; Biotechnology sector by 6.05 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly weak market backdrop."
      },
      {
        "title": "Piramal Pharma Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-valuation-shifts-signal-renewed-price-attractiveness-3969395",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PiramalPharmaLt_valuationdot_3969395.png",
        "date": "2026-04-30 08:00:57",
        "description": "Piramal Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent dip in share price and ongoing sector headwinds. This change reflects a significant reappraisal of the company’s price-to-earnings and price-to-book value metrics relative to its historical averages and peer group, signalling potential opportunities for investors amid a challenging pharmaceuticals and biotechnology landscape."
      },
      {
        "title": "Are Piramal Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-piramal-pharma-ltd-latest-results-good-or-bad-3969122",
        "imagepath": "",
        "date": "2026-04-29 19:17:22",
        "description": "Piramal Pharma Ltd's latest financial results for Q4 FY26 reveal a complex situation characterized by stable revenue but significant challenges in profitability. The company reported net sales of ₹2,751.77 crores, reflecting a marginal decline of 0.08% year-on-year, yet this stability in revenue contrasts sharply with the company's net profit, which fell to a loss of ₹8.83 crores, marking a significant year-on-year deterioration.\n\nThe operating margin, excluding other income, contracted to 16.74%, down 362 basis points from the previous year, indicating pressures on profitability likely driven by rising operational costs. Additionally, the profit after tax (PAT) margin turned negative at -0.32%, a stark decline from the positive 5.57% reported in Q4 FY25. This suggests that while revenue levels were maintained, the underlying operational efficiency and cost management faced significant hurdles.\n\nSequentiall..."
      },
      {
        "title": "Piramal Pharma Ltd Reports Strong Quarterly Turnaround with Robust Revenue and Margin Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-reports-strong-quarterly-turnaround-with-robust-revenue-and-margin-gains-3968291",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PiramalPharmaLt_fintrenddot_3968291.png",
        "date": "2026-04-29 11:00:11",
        "description": "Piramal Pharma Ltd has demonstrated a significant financial turnaround in the quarter ended March 2026, reversing a negative trend with impressive revenue growth and margin expansion. The company’s latest quarterly results reveal a marked improvement in profitability metrics, signalling renewed operational strength amid a challenging pharmaceutical sector backdrop."
      },
      {
        "title": "Piramal Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/piramal-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-3967550",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PiramalPharmaLt_technicaldot_3967550.png",
        "date": "2026-04-29 08:04:03",
        "description": "Piramal Pharma Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend as of late April 2026. Despite a day decline of 2.64% to close at ₹164.30, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and volume-based metrics. This article analyses these technical parameters in detail, contextualising the stock’s recent performance against broader market trends and its historical returns."
      }
    ],
    "total": 15,
    "sid": "1003728",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/piramal-pharma-1003728"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
      "datetime": "05-Jun-2026",
      "details": "Please find enclosed intimation of allotment of ESOPs.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "03-Jun-2026",
      "details": "Permanent revocation of closure directions for Companys Dahej Site",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "01-Jun-2026",
      "details": "Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Piramal Pharma Ltd has declared <strong>1%</strong> dividend, ex-date: 16 Jul 25",
          "dt": "2025-07-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Piramal Pharma Ltd has announced <strong>5:46</strong> rights issue, ex-date: 02 Aug 23",
          "dt": "2023-08-02",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Piramal Pharma Ltd is Rated Sell by MarketsMOJO

2026-05-13 10:10:03

Piramal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Piramal Pharma Gains 12.13%: 5 Key Factors Driving the Week’s Rally

2026-05-09 11:02:14

Key Events This Week 4 May: Flat quarterly financial trend reported amid mixed performance 5 May: Technical momentum shifts with mildly bearish signals 7 May: Intraday high surge of 8.42% and exceptional volume spike 7 May: Surge in value trading and institutional interest 7 May: Exceptional volume surge amid strong price rally Week OpenRs.160.30...

Piramal Pharma Ltd Sees Exceptional Volume Surge Amid Strong Price Rally

2026-05-07 12:00:06

Piramal Pharma Ltd (PPLPHARMA) has emerged as one of the most actively traded stocks on 7 May 2026, registering a remarkable surge in volume and price amidst heightened volatility. The pharmaceutical and biotechnology small-cap stock outperformed its sector and broader market indices, signalling strong investor interest despite a recent downgrade in its mojo grade from Hold to Sell.

Piramal Pharma Ltd Sees Surge in Value Trading Amid Volatility and Institutional Interest

2026-05-07 12:00:05

Piramal Pharma Ltd (PPLPHARMA) emerged as one of the most actively traded stocks by value on 7 May 2026, registering a remarkable 12.39% intraday gain and outperforming its sector by over 14%. The pharmaceutical small-cap has attracted significant institutional interest, with trading volumes soaring to nearly 3 crore shares and a total traded value exceeding ₹551 crore, signalling heightened investor participation amid volatile market conditions.

Piramal Pharma Ltd Surges 8.42% to Day's High of Rs 175.7 — Outperforms Sector by 6.05 Percentage Points

2026-05-07 11:16:01

The Sensex declined 0.18% on 7 May 2026, while Piramal Pharma Ltd surged 8.42%, outperforming its Pharmaceuticals & Biotechnology sector by 6.05 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly weak market backdrop.

Piramal Pharma Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-04-30 08:00:57

Piramal Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent dip in share price and ongoing sector headwinds. This change reflects a significant reappraisal of the company’s price-to-earnings and price-to-book value metrics relative to its historical averages and peer group, signalling potential opportunities for investors amid a challenging pharmaceuticals and biotechnology landscape.

Are Piramal Pharma Ltd latest results good or bad?

2026-04-29 19:17:22

Piramal Pharma Ltd's latest financial results for Q4 FY26 reveal a complex situation characterized by stable revenue but significant challenges in profitability. The company reported net sales of ₹2,751.77 crores, reflecting a marginal decline of 0.08% year-on-year, yet this stability in revenue contrasts sharply with the company's net profit, which fell to a loss of ₹8.83 crores, marking a significant year-on-year deterioration. The operating margin, excluding other income, contracted to 16.74%, down 362 basis points from the previous year, indicating pressures on profitability likely driven by rising operational costs. Additionally, the profit after tax (PAT) margin turned negative at -0.32%, a stark decline from the positive 5.57% reported in Q4 FY25. This suggests that while revenue levels were maintained, the underlying operational efficiency and cost management faced significant hurdles. Sequentiall...

Piramal Pharma Ltd Reports Strong Quarterly Turnaround with Robust Revenue and Margin Gains

2026-04-29 11:00:11

Piramal Pharma Ltd has demonstrated a significant financial turnaround in the quarter ended March 2026, reversing a negative trend with impressive revenue growth and margin expansion. The company’s latest quarterly results reveal a marked improvement in profitability metrics, signalling renewed operational strength amid a challenging pharmaceutical sector backdrop.

Piramal Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-04-29 08:04:03

Piramal Pharma Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend as of late April 2026. Despite a day decline of 2.64% to close at ₹164.30, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and volume-based metrics. This article analyses these technical parameters in detail, contextualising the stock’s recent performance against broader market trends and its historical returns.

View All News